Brand Name
Ekterly
Generic Name
Sebetralstat
View Brand Information FDA approval date: July 03, 2025
Classification: Plasma Kallikrein Inhibitor
Form: Tablet
What is Ekterly (Sebetralstat)?
EKTERLY® is indicated for the treatment of acute attacks of hereditary angioedema in adult and pediatric patients aged 12 years and older. EKTERLY ® is a plasma kallikrein inhibitor indicated for the treatment of acute attacks of hereditary angioedema in adult and pediatric patients aged 12 years and older.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment